The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients

Journal of Neural Transmission

Volumn 110, Issue 6, 2003, Pages 659-669

  Werber, E A ^a   Gandelman Marton, R ^b   Klein, C ^b   Rabey, J M ^b  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Cholinesterase inhibitors; Cognitive assessment; Dementia; P300

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; PROTEIN P300; RIVASTIGMINE; TACRINE;

ADULT; AGED; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; LATENT PERIOD; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; VALIDATION PROCESS;

ACETYLCHOLINE; AGED; CARBAMATES; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEMENTIA; ELECTROENCEPHALOGRAPHY; EVENT-RELATED POTENTIALS, P300; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; PHENYLCARBAMATES; PIPERIDINES; PROSPECTIVE STUDIES; REACTION TIME; TACRINE; TREATMENT OUTCOME;

EID: 0038521162     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-003-0817-9     Document Type: Article

References (36)

1. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders (DSM - IV). American Psychiatric Association, Washington DC
2. Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF (1994) Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative. Arch Neurol 51(12): 1198-1204
3. Celesia GG (1990) Clinical utility of long latency "cognitive" event related potentials (P3): editorial comment. Electroencephalogr Clin Neurophysiol 76: 1
4. Coull JT (1998) Neural correlates of attention and arousal: insights from electrophysiology, functional neuroimaging and sychopharmacology. Prog Neurobiol 55(4): 343-361
5. Dierks T, Frolich L, Maurer K (1994) Event-related potentials and psychopharmacology. Cholinergic modulations of P300. Pharmacopsychiatry 27(2): 72-74
6. Donchin E (1987) The P300 as a metric for mental workload. Electroencephalogr Clin Neurophysiol [Suppl] 39: 338-343
7. Folstein MF, Folstein SE, McHugg PR, Mohs RC, Davis KL (1975) "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 2: 189-198
8. Frodl-Bauch T, Bottlender R, Hegerl U (1999) Neurochemical subsrates and neuroanatomical generators of the event related P300. Neuropsychobiol 40(2): 86-94
9. Geisler MW, Polich J (1990) P300 and time of day: circadian rhythms, food intake, and body temperature. Biol Psychol 31(2): 117-136
10. Goodin DS (1990) Clinical utility of long latency "cognitive" event related potentials P3. The pros. Electroencephalogr Clin Neurophysiol 76: 2-5
11. Goodin DS, Squires KC, Starr A (1978) Long latency event related components of the auditory evoked potentials in dementia. Brain 101: 635-648
12. Halgren E, Marinkovic K, Chauvel P (1998) Generators of the late cognitive potentials in auditory and visual oddball tasks. Electroencephalogr Clin Neurophysiol 106(2): 156-164
13. Hammond EJ, Meador KJ, Aung Dir R, Wilder BJ (1987) Cholinergic modulation of human P3 event related potentials. Neurology 37: 346-350
14. Jensen M, Basun H, Lanfelt L (1995) Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett 186: 189-191
15. Kok A (2001) On the utility of P3 amplitude as a measure of processing capacity. Psychophysiology 38(3): 557-577
16. Krall JK, Srameek JJ, Cutler NR (1999) Cholinesterase inhbitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacother 33: 441-450
17. Kugler CF, Taghavy A, Platt D (1993) The event related P300 potential analysis of cognitive human brain aging a review. Gerontology 39(5): 280-303
18. Kumar V, Anand R, Messina J, Hartman R, Veach J (2000) An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 7(2): 159-169
19. Meador KJ, Loring DW, Davis HC, Patel BR, Adams RJ, Hammond EJ (1989) Cholinergic and serotoninergic effects on the P3 potential and recent memory. J Clin Exp Neuropsychol 11: 252-260
20. Meador KJ, Loring DW, Hendrix N, Nichols ME, Oberzan R, Moore EE (1995) Synergistic anticholinergic and antiserotoninergic effects in humans. J Clin Exp Neuropsychol 17(4): 611-621
21. Michalewski HJ, Rosenberg C, Starr A (1986) Event related potentials in dementia. In: Evoked potentials. Alan R Liss, pp 521-528
22. Moriearty PL, Seubert P, Galasko D, Markwell S, Unni L, Vicari S, Becker RE (1999) Effects of time and cholinesterase inhibitor treatment on multiple cerebrospinal fluid parameters in Alzheimer's disease. Methods Find Exp Clin Pharmacol 21(8): 549-554
23. Nordberg A (1996) Functional studies of new drugs for the treatment of Alzheimer's disease. Acta Neurol Scand [Suppl] 165:137-144
24. Perry E, Walker M, Grace J, Perry R (1999) Acetylcholine in mind: a neurotransmitter correlate of conciousness? Trends Neurosci 22(6): 273-280
25. Pfefferbaum A, Ford JM, Kraemer HC (1990) Clinical utility of long latency "cognitive" event related potentials (P3): the cons. Electroencephalogr Clin Neurophysiol 76: 6-12
26. Polich J (1998) P300 clinical utility and control of variability. J Clin Neurophysiol 15(1): 14-33
27. Portin R, Kovala T, Polo-Kantola P, Revonsuo A, Muller K, Maikiainen E (2000) Does P3 reflect attentional or memory performances, or cognition more generally? Scand J Psychol 41(1): 31-40
28. Potter DD, Pickles CD, Roberts RC, Rugg MD (2000) Scopolamine impairs memory performance and reduces frontal but not parietal visual P3 amplitude. Biol Psychol 52(1): 37-52
29. Reeves RR, Struve FA, Patrick G, Booker JG, Nave DW (1999) The effect of donepezil on the P300 auditory and visual cognitive evoked potentials of patients with Alzheimer's disease. Am J Geriatr Psychiatry 7(4): 349-352
30. Rosen WG et al. (1984) A new rating scale for Alzheimer's disease. Am J Psych 141: 1356-1364
31. Semlitsch HV, Anderer P, Saletu B (1992) Topographic mapping of long latency "cognitive" event - related potentials (P 300): a double-blind, placebo-controlled study with amantadine in mild dementia. J Neural Transm [PD Sect] 4: 319-336
32. Thomas A, Iacono D, Bonanni L, D'Andreamatto G, Onfori M (2001) Donepezil' rivastigmine, and vitamin E in Alzheimer disease: combined P300 event-related potentials/neuropsychologic evaluation over 6 months. Clin Neuropharmacol 24(1): 31-42
33. Van Gool WA, Waardenburg J, Posthumus Meyjes FE, Weinstein HC, de Wilde A (1991) The effect of tetrahydroaminoacridine (THA) on P300 in Alzheimer's disease. Biol Psychiatry 30: 953-957
34. Van Nostrand WE, Wagner SL, Shankle WR, et al. (1992) Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci USA 89:2551-2555
35. Wade J, Hachinski V (1986) Revised ischemic score for diagnosing multi-infarct dementia. J Clin Psychiatry 47(8): 437-438
36. Werber EA, Rabey MJ (2001) The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 108(11): 1319-1325